This compound is a potent and selective inhibitor of the delta isoform of phosphoinositide 3-kinase (PI3K), playing a key role in cell signaling pathways related to growth, survival, and immune cell inflammation. It is developed for anticancer therapies and treatment of immune disorders.

In cancer treatment, particularly hematologic malignancies such as leukemia, lymphoma, and myeloma, it inhibits cancer cell proliferation and promotes apoptosis, especially in cells with dysregulated PI3K pathway activity.

Additionally, it shows potential for treating chronic immune-mediated inflammatory conditions, such as rheumatoid arthritis and systemic lupus erythematosus (SLE), by significantly suppressing B lymphocyte and T cell activation.

In vitro and in vivo studies highlight its high specificity and reduced side effects compared to prior PI3K inhibitors, positioning it as a promising lead for new therapeutics in oncology and immunology.